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Open access under CC BA gene encoding delta 9 desaturase (D9DS), an integral membrane protein, is being considered for incor-
poration into oilseed crops to reduce saturated fatty acids and thus improve human nutritional value.
Typically, a safety assessment for transgenic crops involves purifying heterologously produced transgenic
proteins in an active form for use in safety studies. Membrane-bound proteins have been very difﬁcult to
isolate in an active form due to their inherent physicochemical properties. Described here are methods
used to derive enriched preparations of the active D9DS protein for use in early stage safety studies.
Results of these studies, in combination with bioinformatic results and knowledge of the mode of action
of the protein, along with a history of safe consumption of related proteins, provides a weight of evidence
supporting the safety of the D9DS protein in food and feed.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Development of oils with reduced saturated fatty acid content is
desirable for the improvement of nutrition and the overall health
of consumers. One way to accomplish this is by genetically modi-
fying oil seed crops (e.g. canola and soybean) with a gene encoding
acyl-CoA delta 9 desaturase (D9DS), an integral membrane protein
that catalyzes desaturation of saturated fatty acids at the C9-C10
position to produce unsaturated fatty acids (Stukey et al., 1990).
The enzyme uses acyl-CoA as a substrate and requires O2, NADH,
and cytochrome b5 reductase for activity. The substrate speciﬁcity
of D9DS could be broad, and in one very well studied case, the rat
liver microsomal stearoly-CoA deaturase was active on acyl-CoA
substrates containing 12 to 19 carbon fatty acyl chains (Enoch
et al., 1976). The active site of the related, soluble acyl-(ACP) delta
9 desaturase consists of eight conserved histidine residues that
chelate two molecules of iron. The function and sequence compar-
ison of the membrane-bound acyl-CoA delta 9 desaturase indicates
this enzyme also uses a histidine coordinated diiron center.
(Shanklin and Cahoon, 1998). The acyl-CoA delta 9 desaturase en-
zyme is expressed exclusively in the smooth endoplasmic reticu-
lum (ER), and no apparent N-terminal signal sequences, ER
retention motifs, or consensus glycosylation sites are present in
the enzyme (Stukey et al., 1990). The D9DS gene from Aspergillus: +1 317 337 3249.
uri).
Y-NC-ND license.nidulans (Folkerts and Merlo, 2002) was chosen as a gene candidate
for genetic modiﬁcation of canola. This protein shares 40% identity
with the D9DS isolated from the yeast Saccharomyces cerevisiae
(Stukey et al., 1990) that is used commonly in baking and brewing
and the Fe-binding histidine residues appear to be conserved. The
D9DS protein is 93% identical to a corn (Zea mays) protein (Gen-
bank accession NP_001169125.1), although it would be desirable
to verify the presence of this protein in maize grain to rule out
an erroneous entry in the Genebank database.
The next generation of transgenic crops will likely include those
that contain genes coding for membrane-bound and other intracta-
ble proteins (i.e. those difﬁcult to purify in active form). The well
documented difﬁculty in purifying membrane-bound proteins in
an active form makes it challenging to conduct safety studies that
have routinely been conducted with puriﬁed, active protein to sup-
port the registration of GM crops. Functional expression of mem-
brane-associated proteins (e.g. the G-protein coupled receptors)
is most commonly pursued in yeast (Pichia), mammalian, Esche-
richia coli and insect cell systems (Tate, 2001). Published research
on membrane-bound protein expression suggests that, in general,
homologous expression is far better at producing functional mem-
brane-bound proteins compared with heterologous expression
(Tate, 2001). Even with the recent developments in membrane pro-
tein expression, such as specialized expression systems and cell
free expression systems, it is still challenging to obtain expression
at a level comparable to what can be achieved for soluble proteins
(Bill et al., 2011). There are no examples in the literature for
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active form, and therefore the traditional safety assessment with
proteins made in heterologous system is not feasible (e.g. mouse
acute oral).
In addition to protein expression levels, use of routine safety
assessment routes for D9DS is further complicated in two addi-
tional areas. (1) Demonstration of puriﬁed D9DS activity requires
the reconstitution of the desaturase and cytochrome b5 reductase
into a membrane environment. This has traditionally been accom-
plished by generating liposomes or by incubating the isolated
desaturase with microsomes which are deﬁcient of desaturase
activity on their own (Joshi et al., 1977). This is further complicated
by the need to achieve the appropriate component ratios. (Enoch
et al., 1976) (2) Puriﬁed D9DS tends to aggregate and would need
to be mixed with lipids or other proteins to reduce aggregation as
prolonged detergent exposure is detrimental to activity. (Strittmat-
ter and Enoch, 1978). Hence ‘‘stabilization’’ of pure D9DS could
potentially confound toxicology results. Nevertheless, as a logical
ﬁrst step in developing a strategy for safety assessment with mem-
brane-bound proteins, we expressed D9DS in multiple expression
hosts and carried out a preliminary safety assessment using a novel
strategy. Here we describe multiple expression systems, isolation
procedures, and report the relative success of each system. We also
describe the safety studies conducted with the resulting enriched
extracts from insect cells. Finally, we describe the mode-of-action
and bioinformatic investigations that bear on the safety assess-
ment of the D9DS protein.2. Methods and materials
2.1. Construction of expression vectors
For expression in E. coli, the gene coding for acyl-CoA delta 9 desaturase was
cloned under the control of the T7 promoter in vector pET30a (Promega, Madison,
WI). The recombinant plasmid was transformed into BL21 (DE3) host strain and the
protein was expressed using the manufacturer’s recommended conditions (Prome-
ga, Madison, WI). For mammalian expression, the d9ds coding sequence was cloned
into a pCDNA4/TO vector according to the manufacturer’s protocol (Invitrogen,
Carlsbad, CA). Human kidney cells were co-transfected with d9ds/pCDNA4/TO and
the tetracycline repressor pCDNA6/TR using the Profection mammalian transfection
kit (Promega, Madison, WI). Expression was induced 48 h following transfection,
with 1 lg/mL tetracycline for an additional 24–48 h. Cells were harvested and
D9DS protein was assessed by Western blot using anti-D9DS polyclonal antibodies
raised against N- and C-terminal polypeptides of the D9DS protein.
For expression in yeast, d9ds was cloned into pPICZ a expression vector accord-
ing to the manufacturer’s (Invitrogen, Carlsbad, CA) protocol. For transformation,
linearized vector was introduced into the X-33 Pichia strain using electroporation
and transformants were selected on Zeocin. Selected colonies were grown in
100 mL of Buffered Complex Glycerol medium (complete medium) or minimal
media at 28–30 C to an OD600 of 2–6, and expression was induced by resuspend-
ing cells in medium containing methanol (0.5% ﬁnal concentration). Aliquots at 0, 1,
2, and 3 days were analyzed for expression by immunoblotting with anti-D9DS
antibodies. For expression in insect cells, the d9ds gene was cloned into the baculo-
virus vector pAcSG2 containing a Kozak translation initiation signal at the 5’ end
(continued below).
2.2. Generation of recombinant baculovirus
Spodoptera frugiperda Sf9 cells were transfected with the plasmid pAcSG2 con-
taining the d9ds gene using BacPAK6 viral DNA and Bacfectin transfection reagent
following the manufacturer recommended protocols (Clontech, Mountain View,
CA). To amplify a high titer stock of the recombinant plasmid, a 50-mL culture of
Sf9 cells was seeded at 2  106 cells/mL and infected with 1 mL of a viral plaque
suspension. The culture was incubated 140 rpm at 27 C for 72 h. After 72 h, the cul-
ture was clariﬁed and the supernatant was used as a high titer virus stock.
2.3. Scale-up of acyl-CoA delta 9 desaturase in expresSF+ cells
Once a high titer virus stock was generated, sufﬁcient virus was available for
large scale production of the D9DS protein using expresSF+ cells. To scale up
expression, an 800-mL culture of expresSF+ cells was seeded at 1  106 cells/mL
in SF900 II medium in a 2 L non-bafﬂed Fernbach ﬂask. The culture was incubated
at 27 C at 130 rpm for 72 h. The culture was subsequently split into 6  800 mLcultures which were incubated at 27 C at 130 rpm overnight. The following day,
a sample of the cultures was counted with a hemacytometer, the total number of
cells in each ﬂask was calculated, and the recombinant virus (pAcSG2/d9ds) was
added to a multiplicity of infection of 0.5. Incubation was continued at 27 C at
130 rpm for 48 h. After 48 h, a sample of the culture was taken for Western blot
analysis, and the remaining 4.8 L was used for puriﬁcation of the D9DS protein.
2.4. Preparation of microsomes
Microsomes were prepared from eukaryotic expression hosts as follows. In the
case of Pichia, cells were resuspended 1 g/10 mL of buffer containing 50 mM KPO4,
pH 7.9, 1 mM EDTA, 5% glycerol, 2 mM DTT, 1 mL of protease inhibitor cocktail for
yeast from Sigma per 100 mL of cell lysate and disrupted in a bead beater (SPEX
SamplePrep, Metuchen, NJ) using 0.5 mm beads for 8 cycles of 1 min each with
1 min intervals between each cycle. After disruption, the supernatant was centri-
fuged at 12,000g for 10 min at 4 C followed by a second centrifugation at
100,000g for 1 h at 4 C to recover a microsomal pellet. In the case of insect cells,
baculovirus infected S. frugiperda (Sf9) cells were resuspended in sterile PBS. The
cells were lysed on ice by mild sonication. The cell debris was removed by centri-
fugation at 10,000g for 20 min and the supernatant was further centrifuged at
100,000g for 90 min to obtain the microsome pellet.
2.5. Acyl-CoA delta 9 desaturase assay
Once the microsomes were isolated, the D9DS enzyme activity was measured
by a modiﬁed assay based on the procedure described by Young (2003). To elimi-
nate the need for radioactivity, heptadecanoyl-CoA was used in place of 14C-palmi-
toyl-CoA and product formation was measured via GC-ﬂame ionization detector
(FID). In detail, microsomes were incubated in a 30 C shaking water bath
(150 rpm) for 30 min under the following conditions: 90 lM heptadecanoyl-CoA,
70 mM potassium phosphate buffer pH 7.2, and 1 mM NADH. The reaction was
stopped by adding an equal volume of 10% KOH in methanol and samples were
saponiﬁed by incubating on an orbital shaker at 80 C for 30 min. The product
and substrate of the oxidation reaction were measured after saponiﬁcation of the
microsomes. The resulting free fatty acids were extracted by acidifying the reaction
with 0.5 mL of 6 N HCl. The protonated acids were extracted with hexane and the
resulting organic fraction was evaporated to dryness. The dry residue was resus-
pended in 0.5 mL MeOHCl 3 N and reacted at 80 C for 30 min. The resulting fatty
acid methyl esters (FAMEs) were extracted in hexane and evaporated to dryness
prior to reconstitution in 0.1 mL hexane containing 100 ppm tridecanoate-methyl
ester as an internal standard (IS). The quantitation of the FAMEs was achieved by
direct comparison of the peak area with a commercial calibration standard (Mat-
reya, rape seed #1083) containing the IS. The stearate methyl ester response was
used for quantiﬁcation of heptadecanoate and heptadecenoyl methyl esters. The
separation of resulting FAMEs was achieved using Agilent GC6890 equipped with
a capillary column BPX-70 (SGE, 15 m  0.25 mm  0.25 lm). The oven was pro-
grammed as follows: splitless injection at 60 C for 1.3 min followed by 41.3 C/
min ramping to 150 C then to 180 C at 9.1 C/min and ﬁnishing at 220 C at
41.3 C/min to be held for 1.8 min. The injection port was maintained at 230 C
and the detector at 240 C. The make-up gas was nitrogen at 25 mL/min and the
carrier gas was hydrogen at 40 mL/min. Reported FAMEs concentrations were ex-
pressed in ppm.
2.6. Membrane-bound protein extraction and puriﬁcation
The microsomes were thawed and kept on ice. Detergent or combinations of
detergents, ranging from 0.1% to 2% (v/v) were added and the reaction was incu-
bated at 4 C overnight with stirring. Samples were then subjected to ultracentrifu-
gation, as described above, and the supernatant was collected for column
separation. In most cases, sample was further diluted in the extraction buffer to re-
duce the detergent concentration to less than 0.5% ﬁnal concentration. Detergent
Fos-choline-12 was selected for production and puriﬁcation after scouting experi-
ments eliminated  50 other detergents from various classes. The solution was ap-
plied onto a 5 mL or a tandem 5 mL nickel-HP column (GE Healthcare, Piscataway,
NJ), and washed in buffer A (50 mM Tris–HCl, pH 7.5, 0.3 M KCl, 5% glycerol, 0.2%
FC-12, and 20 mM imidazole). Bound protein samples were eluted from 20–
500 mM imidazole gradient in buffer A and collected in individual fractions. Sam-
ples containing D9DS were pooled, either concentrated on a 5 mL Heparin afﬁnity
column (GE Healthcare) or further separated on a Mono S column (GE Healthcare)
using 0–1 M NaCl salt gradient. SDS–PAGE was used to monitor separation and
Western blot conﬁrmed sample identity using polyclonal antibodies.
2.7. Bioinformatic assessment of protein allergenicity
For the allergenicity assessment, the amino acid sequence of the D9DS was
compared with a peer-reviewed database containing 1603 known and putative
allergens as well as celiac-induction proteins residing in the FARRP dataset (Version
12, Released in February 2012, University of Nebraska, http://www.allergenon-
line.org). Potential identities between the D9DS and proteins in the allergen
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parameters (Matrix = BLOSUM50; Gap Penalties = 12/-2; ktup = 2; except Expec-
tation = 100). The FASTA search was run by an in-house Perl script on an internal
UNIX computer with Linux operating system. If a query sequence is longer than
80 amino acids, the script parses the query sequence into a complete (overlapping)
set of 80 amino acid long fragments and each fragment is subjected to a FASTA
search. A greater than 35% identity threshold over any 80 or more amino acid se-
quences between a query sequence and an allergen was used to indicate the poten-
tial for cross-reactivity. To ensure that high identity over a short stretch (for
example, 80% over 60 amino acids) will not be overlooked, a calculation, (Iden-
tity%  number of overlapped amino acids)/80, was implemented as a conversion
to check the criteria of >35% over 80 amino acids when the FASTA alignment (over-
lapped amino acids) is less than 80 amino acids. The D9DS protein sequence was
also screened for any matches of 8 contiguous amino acids to the allergens con-
tained in the database noted above. This was done using an in-house Perl script that
generates all sequentially possible (overlapping) 8-residue peptides from a query
protein, followed by Fuzzpro program (Emboss Package v2.10.0) search that com-
pares each query sequence with all allergen sequences in the database for perfect
matches.
2.8. Bioinformatics assessment of protein toxicity
To assess potential toxicity of the D9DS protein, a search for similarity of pro-
tein sequences was conducted using the BLASTp program (Altschul et al., 1990).
The amino acid sequence of the D9DS was queried using the BLASTp (Version
2.2.21+) against GenBank non-redundant protein sequences (update to February
10, 2012), which incorporates non-redundant entries from all GenBank and RefSeq
nucleotide translations (Genpept ‘‘nr’’) along with protein sequences from SWISS-
PROT (http://www.expasy.org/sprot/), PIR (http://pir.georgetown.edu/), PRF
(http://www.prf.or.jp/aboutdb-e.html), and PDB (http://www.wwpdb.org/). The
search was done through the BLAST program installed on an internal UNIX com-
puter with default settings (Matrix = BLOSUM62, Gap Costs = Existence: 11, Exten-
sion: 1) except that a cutoff expectation E-value of 1.0 was used to generate
biologically meaningful similarity between the query sequences and proteins in
the database, the low complexity ﬁltering was turned off, and the sequence descrip-
tion and alignment display were set to 5000 alignments. Although a statistically sig-
niﬁcant sequence similarity generally requires a match with an expectation value
less than 0.01, a cutoff of E()<1.0 insures that proteins with even limited similarity
will not be overlooked in the search (Pearson, 2000).
2.9. Heat treatment of acyl-CoA delta 9 desaturase
The D9DS microsomal preparation (prepared as described earlier) was thawed
on ice, vortexed, and dispensed into 5 microfuge tubes in 150 lL aliquots. The con-
trol sample was held on ice and the others were heated at 30, 50, 70, or 95 C for
30 min. After heat treatment, all samples were immediately placed on ice. Aliquots
were analyzed by Western blot (probed with a D9DS speciﬁc polyclonal rabbit anti-
body) and evaluated for enzymatic activity by monitoring the formation of 17:1 as
described earlier.
2.10. Digestibility of partially puriﬁed and microsomes expressing acyl-CoA delta 9
desaturase
Equimolar (0.074 mM) solutions of the control substances were prepared as
follows: BSA (pepsin labile) was solubilized by weighing 24.7 mg of powder in a
15-mL centrifuge tube and adding 5 mL of Milli-Q water. b-lactoglobulin A (pepsin
resistant) was solubilized by weighing 7.5 mg of powder in a 15-mL centrifuge tube
and adding 5 mL of Milli-Q water. The varying amounts of the test and control sub-
stances reﬂect differences in purity and molecular weight. Simulated gastric ﬂuid
(SGF, pH 1.2) containing a ﬁnal concentration of approximately 0.32% (w/v) pep-
sin (Sigma Aldrich, St. Louis, MO, catalog #P6887, 89% w/w pure, 3,600 units of
activity/mg protein) was prepared as recommended in The United States Pharma-
copeia, 1995. Pepsin was solubilized by weighing 0.1904 g of powder and dissolving
into 50 mL of 34 mM NaCl, pH 1.2. Methods generally followed those of (Herman
et al., 2005; Herman et al., 2007)
The digestions for microsomal-derived D9DS, BSA, and b-lactoglobulin A were
performed for time intervals of approximately 15 s, 30 s, 1, 2, 4, and 8 min in a
water bath set to 37 C. The three samples; D9DS microsomes (that were thawed
on ice), BSA, and b-lactoglobulin A were digested as follows: Three 2.75-mL aliquots
of SGF were placed in the 37 C water bath. After 5 min, 250 lL of the D9DS micro-
somal solution (as prepared above), 0.74 mM BSA, and 0.74 mM b-lactoglobulin A
were each added to a separate vial of the SGF and a timer was set. After each spec-
iﬁed incubation interval, 100 lL of the reaction mixture was removed and added to
tubes containing stop solution (40 lL of 200 mM sodium carbonate, pH 11.0). The
stopped reactions were then placed on ice until all of the time points were sampled
for the three proteins. An SGF control was prepared by substituting water for the
sample protein and incubating for the duration of the experiment at 37 C. The
SGF control was prepared as follows: A 2.75-mL aliquot of SGF was heated in a
37 C water bath for 5 min, 250 lL of Milli-Q water was added and a timer wasset. A 100 lL aliquot was immediately removed as the zero time point and placed
into a tube containing the stop reaction (40 lL of 200 mM sodium carbonate, pH
11.0), when all digestion reactions for all proteins were complete, one ﬁnal aliquot
was taken at the duration of the experiment. For each of the proteins above, a zero
time point (neutralized control) was prepared as follows: First, a 91.7 lL aliquot of
SGF was heated for 5 min at 37 C and stopped with 40 lL 200 mM sodium carbon-
ate, then 8.3 lL of the respective protein was added to the solution.
Aliquots of the neutralized and digested proteins were mixed with equal vol-
umes of Laemmli sample buffer (Bio-Rad), containing 5% freshly added 2-mercap-
toethanol (Bio-Rad) and heated for 5 min at 95 C. Single 4–12% Bis–Tris
polyacrylamide gels (Bio-Rad) of BSA b-lactoglobulin A, and duplicate gels of
D9DS were prepared. One gel was stained with Gel-Code Blue (Thermo-Pierce)
and the other was transferred to a nitrocellulose membrane and probed with
anti-D9DS polyclonal antibodies and detected with anti-rabbit HRP-labeled anti-
bodies and chemiluminescent detection. The optical densities (ODs) of three diges-
tion fragments of the microsomal-derived D9DS observed on the ﬁlm were
determined by scanning the Western blot ﬁlm with a densitometer similar to the
procedure described by Brussock and Currier (1990). The densities of each fragment
were regressed against the digestion time between 15 s and 8 min (time of appear-
ance till last time point) using a three-parameter exponential model (OD = aekT + b,
where a = y  intercept; b = asymptote and k = 1st-order rate constant) using SAS
version 9.1.3. Results and discussion
The safety assessment of proteins expressed in genetically mod-
iﬁed plants routinely requires multi-gram quantities of highly
puriﬁed, active recombinant proteins for toxicological and aller-
genicity studies. Membrane-bound proteins such as D9DS are dif-
ﬁcult to produce at such levels in a highly puriﬁed form. The
ubiquitous nature of this protein and the important function it per-
forms in all living organisms suggest that it is unlikely to be detri-
mental to human health if consumed, however, weight of evidence
studies are needed to address this assumption. D9DS presents two
additional challenges: (1) besides being a membrane-bound pro-
tein; it is not functional when extracted from the membrane and
(2) it requires another membrane-bound accessory protein, cyto-
chrome B5 reductase, for activity. Because of these challenges,
D9DS was expressed in multiple expression systems, and several
strategies were explored for safety assessment.3.1. Expression of acyl-CoA delta 9 desaturase
A broad range of expression systems such as E. coli, mammalian,
Pichia, and insect cells were explored to ensure successful produc-
tion of D9DS in quantities that would enable a thorough safety
assessment. Expression levels in E. coli and mammalian cell culture
systems were very low; only P. pastoris and insect cells provided a
sufﬁcient level of expression (milligrams per liter) to warrant mov-
ing forward with enrichment and puriﬁcation. Most of the puriﬁca-
tion work was performed with D9DS expressed in these two
systems. Fatty acid analysis of insect and Pichia cells expressing
D9DS demonstrated a decrease in C16:1 and an increase in C18:1
fatty acids compared with control cells suggesting that the D9DS
was expressed and functional (data not shown). Membrane locali-
zation in insect and Pichia cells was conﬁrmed by evaluating
microsomes by Western blot analysis for the presence of D9DS.
D9DS was present in the microsomal fraction and not in the solu-
ble fraction conﬁrming membrane localization (Fig. 1).
When a non-natural substrate heptadecanoic acid (C 17:0) was
used to verify that the expressed proteins were functional, micro-
somes from insect cells and P. pastoris expressing D9DS were able
to convert 12% and 35%, respectively, of the added substrate to
heptadecenoic acid (C 17:1) indicating that the expressed D9DS
was active in both host systems. Subsequent experiments targeted
a conversion of <10% to ensure that subrate was not limiting and
supported a linear reaction rate. We also examined the fatty acid
proﬁle of whole cells expressing D9DS. In P. pastoris and insect cells
Fig. 1. Western hybridization analysis of ExpressSF cells expressing acyl-CoA delta
9 desaturase after processing for the isolation of microsomes. Lane 1 –ExpresSF+
cells expressing the desaturase; Lane 2 – microsome pellet after 100,000g
centrifugation; Lane 3 –supernatant after centrifugation at 100,000g. Arrow
indicates the full-length acyl-CoA delta 9 desaturase protein.
Fig. 2. Comparison of acyl-CoA delta 9 desaturase expression in multiple hosts.
Lane 1 - Sf9 cells expressing desaturase; Lane 2 - Sf9 control cells; Lane 3 – Pichia
expressing desaturase; Lane 4 - Pichia host only control; Lane 5 – S. cerevisiae
expressing desaturase; Lane 6 – S. cerevisiae host only control; Lane 7 – A. nidulans
untransformed (source of the desaturase gene). Total proteins from different hosts
were separated by SDS–PAGE (panel A) and probed by western hybridization
analysis with the polyclonal antibody generated against the C-terminal domain of
desaturase expressed in an insoluble form in E. coli.
K.M. Madduri et al. / Food and Chemical Toxicology 50 (2012) 3776–3784 3779expressing D9DS, a clear shift in fatty acid proﬁle was generally
seen, especially for the pool of C18:1.
Western blot analysis of microsomes from the two separate
hosts expressing D9DS indicated that the volumetric productivity
(productivity per unit volume of culture) was comparable
(Fig. 2). Expression of D9DS was examined in Pichia using a quan-
titative Western blot analysis method using the polyclonal anti-
bodies to the C-terminal domain of D9DS. In Pichia D9DS
expressed at 0.8–1 mg/l and in insect cells the expression washigher than Pichia (Fig. 2) indicating that both systems were suit-
able for an early tier safety assessment (Delaney et al., 2008). Spe-
ciﬁcally, mode of action, in vitro digestibility and heat lability,
protein expression level, and dietary exposure of the transgenic
protein could all be assessed for the A. nidulans-derived D9DS pro-
tein. However, it was clear that none of the hosts expressing D9DS
are capable of generating sufﬁcient protein for an in vivo toxicology
assessment which would be required if an early tier assessment
indicated risk (Delaney et al., 2008). Such testing would require
several grams of active puriﬁed protein. To develop suitable
D9DS enrichment methods, the insect cell system was chosen as
a source of D9DS as the native D9DS protein in insect cells is signif-
icantly different both in sequence and size compared with A. nidu-
lans-D9DS facilitating differentiation between native and
transgenic versions. Insect D9DS proteins have been cloned and
characterized (Knipple et al., 1998) and do not contain the cyto-
chrome B5 domain that is present in the A. nidulans-D9DS whereas
yeast D9DS (including P. pastoris) also contains a cytochrome B5
domain. Therefore, the native insect D9DS was less likely to inter-
fere with chromatographic puriﬁcation as it is unlikely to co-elute
with A. nidulans-D9DS.3.2. Puriﬁcation of A. nidulans acyl-CoA delta 9 desaturase
Isolation of sufﬁcient D9DS in an active form posed many chal-
lenges. The ideal detergent needed to be very efﬁcient at extracting
the D9DS from membrane preparations, and at the same time
should not impact stability or interfere with activity. Reconstitu-
tion of the puriﬁed protein in an artiﬁcial membrane is essential
for validating the function of the puriﬁed protein. This is a major
bottleneck in developing puriﬁcation methods to monitor progress
as it is not trivial to reconstitute active protein given the require-
ment for the accessory protein cytochrome b5 reductase (cytb5).
Therefore, a number of detergents were evaluated for their efﬁ-
ciency in extracting D9DS from microsomes and for impact on
activity of D9DS.
Approximately 50 detergents from all classes (ionic, non-ionic
and zwittterionic) were examined for extraction efﬁciency
(Table 1) and 36 were evaluated for interference with the activity
of D9DS. In the latter case, the enzyme’s tolerance for residual
detergent was examined at 0.05% detergent concentration because
higher detergent concentrations were detrimental to activity for all
detergents tested (unpublished data). Initial puriﬁcation work
focused on the detergents which demonstrated low impact on
activity, octyl glucoside and zwittergent 3–10.
As mentioned earlier, activity of the puriﬁed protein could not
be demonstrated without reconstitution of the membrane environ-
ment as cytb5 reductase is required in the artiﬁcial membrane
along with D9DS to enable activity. Our efforts to express cytb5
reductase resulted in very limited success. Therefore, reconstitu-
tion of D9DS activity was attempted with SF9 microsomes from
cells which had not been transfected for D9DS production based
on the method of Joshi et al., 1977. Convincing reconstitution
was not observed. Given these results and that the protein recov-
ery levels with these detergents were not optimal, follow up
extraction efforts focused soley on obtaining high levels of pure
protein. Among the detergents tested, Fos-choline-12 and ASB-14
were found to perform very well in extracting D9DS from micro-
some membranes. As expected, the activity of D9DS was abolished
after extraction with high concentration of detergents as these en-
zymes function only when present in membranes (Chabaud et al.,
1998; Strittmatter and Enoch, 1978). As the level of recombinant
expressed D9DS was only a small fraction of the microsomal prep-
aration, conventional methods (combination of ion exchange, iso-
electric focusing, hydroxyapatite chromatographies) to isolate the
Table 1
Detergents tested for An acyl-CoA delta 9 desaturase (D9DS) extraction efﬁcacy. The types of detergents: A, anionic; C, cationic; N, nonionic; Z, zwitterionic. Abbreviation: NA:
data not available; Purity of detergents from Anatrace was measured by the manufacturer using HPLC analysis. Detergents from other manufacturers were of ultrapure grade
reagent. Extraction efﬁcacy was rated by SDS–PAGE analysis followed by Western blot using a polyclonal antibody for the C-terminal fragment of D9DS, ‘‘’’ indicates no
extraction and recovery; ‘‘+/’’ as non-reproducibly positive extraction; ‘‘ + ’’ as positive extraction; ‘‘++’’ as strong positive extraction; while ‘‘x’’ indicates extraction resulting in
signiﬁcant destruction, where only protein smears were obtained with no distinct protein bands after gel separating. Majority of the detergent concentration examined were from
0.5–2% (v/v) and only a few were used in either <0.5% or >5% depending on their critical micelle concentration (CMC).
Detergent Type Purity (%) Manufacturer Extraction efﬁcacy (recovery)
None, no detergent control 0
ANAPOE-20 N NA Anatrace, Maumee, OH, USA +/
ANAPOE-35 N NA Anatrace +
ANAPOE-58 N NA Anatrace ++
ANAPOE-80 N NA Anatrace +/
ANAPOE- C12E10 N NA Anatrace +
ANAPOE-X-100 N NA Anatrace +
ANAPOE-X-114 N NA Anatrace +
ANZERGENT 3–8 Z 99.6 Anatrace +
ANZERGENT 3–10 Z 99.5 Anatrace +
Apo-10 N NA Calbiochem, Billerica, MA, USA 
ASB-14 Z >98 Calbiochem ++
ASB-14–4 Z NA Calbiochem +
ASB-16 Z NA Calbiochem +
ASB-C8 Z NA Calbiochem 
BRIJ 72 N NA Calbiochem 
C10E8 N NA Calbiochem +/
C12E8 N NA Calbiochem +/
C–DODECAFOS Z 99.5 Anatrace 
CHAPS Z 99.5 Anatrace +
CYMAL-2 N 99.5 Anatrace +
CYMAL-6 N 99.5 Anatrace +/
CYCLOFOS-2 Z 99.5 Anatrace +
CYCLOFOS-5 Z >98 Anatrace +
CYPFOS-3 Z 99.5 Anatrace 
Decyl-D-thiomaltopyranoside N NA Anatrace 
Deriphat 160 N NA Cognis Corp., Cincinnati, OH, USA +
Dodecyl-D-maltoside N 99.5 Anatrace +
Dodecyltrimethylammonium chloride C 98.9 Anatrace 
FOS-choline-10 Z 99.5 Anatrace +
FOS-choline-12 Z 99.5 Anatrace ++
FOS-choline-13 Z >99 Anatrace ++
FOS-choline-16 Z 99.2 Anatrace ++
FOS-choline-ISO-9 Z 99.5 Anatrace 
FOS-choline-UNSAT-11–10 Z >99 Anatrace +
FOS-MEA-8 A 99.5 Anatrace 
Heptyl-D-glucopyranoside N 99.5 Anatrace 
Hexadecyltrimethylammonium chloride C 98.9 Anatrace +
IGEPAL CA-630 (NP-40) N NA Sigma 
LDAO Z 99.5 Anatrace +
LDS A >99 Anatrace x
Na Cholate A NA Anatrace 
Na deoxycholate A 99.5 Anatrace 
NDSB 201 N 100 Calbiochem 
Octaethylene glycol monododecyl ether (C12E8) N 99.5 Anatrace +
Octyl-D-glucopyranoside N >99 Anatrace +
Pentaethylene glycol monodecyl ether N 99.5 Anatrace 
PMAL-C10 Z NA Anatrace 
SDS A Sigma x
Sucrose monodedecanoate N 98.9 Anatrace +
Tridecyl-D-maltopyranoside N 99.5 Anatrace +
Triton X-100 N NA Sigma, St. Louis, MO, USA +
Triton X-114 N NA Sigma +
Tween 20 N NA Sigma +/
Tween 80 N NA Sigma +/
Tergitol NP-9 N NA Sigma 
Undecyl-D-maltopyranoside N 99 Anatrace +
Zwittergent 3–10 Z NA Calbiochem +
Zwittergen 3–14 Z NA Calbiochem +
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explored.
Polyclonal antibodies were raised against the C-terminal soluble
domain immediately following the second TM domain correspond-
ing to amino acids 235–454 expressed in an insoluble form in E. coli
(unpublished results) and were used to monitor the puriﬁcation
process by Western blot. The same polyclonal antibody was used
to purify D9DS, initially by immunoafﬁnity chromatography,although it failed to capture D9DS efﬁciently. Among the various
chromatographic options evaluated, a metal afﬁnity column fol-
lowed by a heparin afﬁnity column was found to be most effective
in enriching D9DS. This method yielded about 500-fold enrichment
with an overall purity of 30–50% in standard PBS buffer. Under
these conditions, the protein maintained good stability though it
did not maintain activity. Further puriﬁcation to remove other host
proteins and/or phosphorylated proteins/lipids resulted in
Table 2
Sequence homology between acyl-CoA delta 9 desaturase and several human and plant fatty acid desaturase and cytochrome b5 proteins.
GenBank accession Description Identity (%)/number of amino acids E-value
NP_005054.3 Stearoyl-CoA desaturase (delta-9-desaturase) [Homo sapiens] 40/267 1  1048
AAD29870.1 Stearoyl-CoA desaturase (delta-9-desaturase) [Homo sapiens] 40/267 1  1048
CAA73998.1 Stearoyl CoA desaturase [Homo sapiens] 40/267 9  1048
NP_001169125.1 Uncharacterized protein LOC100382970 [Zea mays] 93/456 0
BAC43716.1 Putative delta 9 desaturase [Arabidopsis thaliana] 32/234 2  1021
AAK92773.1 Putative delta 9 desaturase [Arabidopsis thaliana] 30/244 2  1020
BAJ91418.1 Predicted protein [Hordeum vulgare subsp. vulgare] 56/394 1  10129
XP_003525924.1 PREDICTED: cytochrome b5-like [Glycine max] 41/75 2  105
XP_003523994.1 PREDICTED: cytochrome b5-like [Glycine max] 41/71 3  105
XP_003636809.1 Cytochrome B5 [Medicago truncatula] 43/67 8  105
XP_003638456.1 Cytochrome B5 [Medicago truncatula] 43/67 2  104
Table 3
Measurement of the effect of heat treatment on acyl-
CoA delta 9 desaturase enzymatic activity. Activity
was measured based on the conversion of a non-
natural C17:0 substrate (to differentiate from back-
ground fatty acids) to a C17:1 product. The initial
speciﬁc activity of the microsomal preparation was
0.13 nmol/min/mg of total protein.
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aggregation issues. From 10 L of insect cell cultures expressing
D9DS, about 1 mg of D9DS at 30–50% purity was obtained. Given
the low recovery and level of purity achieved prior to protein pre-
cipitation, we concluded that preparation and reconstitution of a
functional, puriﬁed D9DS on the scale needed for in vivo toxicology
studies was not feasible.
3.3. Safety assessment
Expression and puriﬁcation studies demonstrated that it is not
feasible to obtain a sufﬁcient amount of high purity D9DS in a func-
tionally active form to enable in vivo toxicology studies. While the
enzyme is ubiquitous and is part of the human diet (including
yeast and corn which have homologous D9DS), assessment of ini-
tial safety was deemed beneﬁcial, but the strategy employed had
to be modiﬁed. Strategies that did not require puriﬁcation of pro-
tein to homogeneity were considered. Feeding studies with micro-
somes from insect cell expressing D9DS were considered for
toxicity assessment. However, the traditional high-dose acute oral
mouse toxicity study is not possible with microsomes as the oral
ingestion of microsomes needed to meet the common dosage of
2000–5000 mg/kg. In addition, ingestion of microsomes might be
deleterious to the health of the animals. For these reasons, animal
toxicity studies with enriched D9DS were not considered feasible
as a part of overall safety assessment and a modiﬁed safety assess-
ment regime was used.
3.4. Potential protein allergenicity and toxicity
When a new transgenic protein is produced in crops, one
assessment considers allergenic potential. Thus far, no single prop-
erty of a protein is known to predict allergenic potential. For this
reason, a weight-of-evidence approach to predicting allergenic risk
has been adopted which considers multiple factors. To assess po-
tential allergenicity of a protein, two criteria for evaluating struc-
tural similarities between query proteins and known allergens
are currently used based on amino acid sequence alignments Co-
dex, 2009; Ladics, 2008 FAO/WHO, 2001). The ﬁrst criterion is a
search over 80-amino-acid stretches (sliding window search) to
detect >35% identity between a query protein and known allergens.
The window size of 80 amino acids was selected to correspond
with a typical domain size in a protein, and recognizes that single
protein domains may contain epitopes that mediate antibody bind-
ing. The second criterion involves evaluating short amino-acid
stretches for identity between the query protein and known aller-
gens although this approach has been criticized for high rate of
false positive and lack of scientiﬁc value (Silvanovich et al. 2006;
Stadler and Stadler, 2003; Goodman et al., 2008; Thomas et al.,
2008; Cressman and Ladics, 2009; Herman et al., 2009). When
the amino acid sequence of the D9DS protein was compared withthe FARRP allergen dataset (Version 12), no over threshold identi-
ties (greater than 35% identity over 80 or more amino acid resi-
dues) were detected in the FASTA search outputs. No matches of
eight or greater contiguous identical amino acids with known
allergens in the database were observed in the entire D9DS se-
quence. These results show that D9DS does not share any signiﬁ-
cant amino acid sequence similarity with known protein allergens.
Another safety assessment of proteins expressed in transgenic
crops is the evaluation of relatedness to known toxins. It has been
reported that assessing the potential toxicity of a protein may in-
clude comparison of the protein sequence to known protein toxin
sequences Codex, 2009. Since there is no commonly recognized
deﬁnition of a protein toxin based on its sequence, a comparison
should be made to a database of all available protein sequences
as a conservative approach. Proteins identiﬁed with statistically
signiﬁcant similarity using a local alignment algorithm are then
evaluated for their relevance as potential toxins. The D9DS protein
is a stearoyl CoA desaturase isolated from the fungus A. nidulans.
This protein has a fatty acid deasaturase domain. Unlike many en-
zymes of this class, it also contains a cytochrome b5 (cytb5) do-
main. Therefore, it was expected to have homology with two
classes of proteins from various species when comparing to other
proteins in a database.
The search of D9DS against the Genbank non-redundant pro-
tein sequences identiﬁed 3007 hits with E-value < 1. As expected,
the majority of the identiﬁed proteins were fatty acid-desaturase
and/or contained a cytb5 domain. Those proteins can be grouped
into 4 categories: fatty acid-desaturase (fatty acid hydrolyase),
cytochromes b5, hypothetically predicted proteins, and nitrate
reductase with very weak similarity with D9DS (E-value
>0.001). Fatty acid-desaturase is a common enzyme found in a
broad range of organisms including human, animal, plants, and
fungus, and bacterium. Cytochromes b5 are ubiquitous electron
transport hemoproteins found in animals, plants, fungi and purple
phototrophic bacteria. None of these proteins returned by the
BLASTp search is associated with toxicity. Furthermore, D9DS
3782 K.M. Madduri et al. / Food and Chemical Toxicology 50 (2012) 3776–3784showed some signiﬁcant sequence similarity with fatty acid-
desaturases from human and plants, and cytochromes b5 from
food crops (Table 2). An uncharacterized maize protein
(NP_001169125.1) is almost identical to D9DS, indicating proteins










































































Fig. 3. Western blot analysis of microsomal-derived acyl-CoA delta 9 desaturase (M.W.
A), SDS PAGE (panel B). Plot of digestion of three digestion fragments of Anacyl-CoA delta
C).desirable to verify that this protein is present in maize grain to
eliminate the possibility of an erroneous entry into the Genebank
database. Therefore D9DS protein contains no signiﬁcant se-
quence similarity with any known toxic protein that is harmful
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9 desaturase showing the ﬁt of a three-parameter exponential decay model (panel
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3.5.1. Biochemical properties
While no signiﬁcant amino-acid sequence homology was seen
to known allergens and protein toxins by sequence analysis, two
additional weight of evidence studies were examined for the active
microsomes bound D9DS or partially puriﬁed soluble protein. Sim-
ulated gastric ﬂuid studies and heat lability were considered as a
part of overall safety assessment to determine the stability of the
D9DS.
3.5.2. Heat treatment of acyl-CoA delta 9 desaturase
Proteins are usually denatured and inactivated by high temper-
atures and the degree of inactivation is dependent upon the tem-
perature and duration of the heat treatment. All heat treatments
conducted as part of this investigation involved temperatures that
occur at or below the temperatures experienced during canola seed
processing (Gunstone, 2004). In canola industrial processing, mul-
tiple steps of heat treatment are usually involved in the production
of the desolventized meal and extraction of oil. For example, dur-
ing pre-pressing of the seed, temperatures of 82 to 100 C are
used in the production of crude canola oil and pressed cake. During
the production of the reﬁned, bleached, and deodorized canola oil
(RBD oil), the oil extracted from canola meal is further processed
by exposing the oil to acid, caustic soaps, bleaching reagents, and
temperatures up to 240 C. This harsh treatment ensures the ﬁnal
RBD oil is completely free from odor and off ﬂavors allowing use
in many aspects of food manufacture.
The thermal stability of D9DS protein was evaluated by heating
microsomal solutions for 30 min at 30, 50, 70, 95 C. The D9DS pro-
tein activity was measured by a modiﬁed enzyme assay based on
the procedure described by Young (2003). The study demonstrated
that the D9DS protein has signiﬁcantly reduced activity when
heated. In the activity assay (the measurement of the conversion
of C17:0 to 17:1), the protein lost greater than 50% of its enzymatic
activity at 30 C and virtually all of the activity was eliminated at
the higher temperatures tested (Table 3). These data indicate that
industrial canola processing would largely inactivate the D9DS
protein.
3.5.3. SGF digestibility of microsomal-derived acyl-CoA delta 9
desaturase
The digestibility of D9DS was assessed according to published
methods that are universally accepted by global regulatory agen-
cies. The digestible and non-digestible control proteins, BSA and
b-lactoglobulin A, respectively, responded as expected as BSA
was not detected at the 30-s time point and b-lactoglobulin A re-
mained readily detectable for the duration of the experiment (data
not shown). The D9DS protein, with an apparent molecular weight
of approximately 52 kDa, was barely detectable at 15 s on theWes-
tern blot for the microsomal-preparation Fig. 3. Three minor frag-
ments of the protein were produced during the digestion, and the
half lives of the three fragments ranged from 12 to 28 s as demon-
strated by quantitative densitometric analysis (Fig. 3). Multiple
time points were were used to calculate the digestion rate and
the rapid digestion of the D9DS protein and fragments leaves little
uncertainty about its digestibility, even in this complex matrix. To
further validate this ﬁnding, a similar experiment was performed
using partially-puriﬁed D9DS and the protein was not detectable
after 30 s and no fragments were observed in any of the time
points (data not shown). This was probably due to protein denatur-
ation that occurred during puriﬁcation resulting in more accessible
protease sites or the digestion of the microsomal-derived D9DS
was slowed by the additional proteins contained in the microsomal
preparation. The undigested D9DS portion of both preparations
also showed dimeric and/or oligomerized forms in addition tothe monomeric 52 kDa band on the Western blot, probably owing
to the complex mixture of the protein sample and aggregation
upon heating.4. Conclusions
The ability to purify active proteins produced from new trans-
genic traits may not be feasible where such proteins are mem-
brane-bound. The membrane-bound protein, D9DS, is an example
of a protein which could not be isolated in an adequate quantity
for traditional toxicology studies using mouse models. Current
weight of evidence information does not indicate any known safety
concerns: (1) D9DS –type proteins are present in food. (2) The
mode of action of the D9DS protein is not associated with any
known safety issues. (3) Bioinformatic studies indicated that the
D9DS protein does not have any biologically relevant similarity
to proteins known to pose a safety risk. (4) Enriched preparations
of active D9DS protein were denatured by heat and readily di-
gested in simulated gastric ﬂuid indicating no remarkable stability
that might increase exposure or persistence relative to normal die-
tary proteins. This information, in combination with the history of
safe consumption of highly related proteins, provides a weight-of-
evidence supporting the human health safety of D9DS as expressed
in oil-seed crops. When transgenic events of interest are selected
animal-feeding studies could also be carried out to conﬁrm safety.5. Conﬂict of Interest
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